Short-chain acyl-CoA dehydrogenase (SCAD) deficiency

An examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms

S. E. Waisbren, H. L. Levy, M. Noble, D. Matern, N. Gregersen, K. Pasley, D. Marsden

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The medical and neurodevelopmental characteristics of 14 children with short-chain acyl-CoA dehydrogenase deficiency (SCADD) are described. Eight were detected as neonates by newborn screening. Three children diagnosed on the basis of clinical symptoms had normal newborn screening results while three were born in states that did not screen for SCADD. Treatment included frequent feedings and a low fat diet. All children identified by newborn screening demonstrated medical and neuropsychological development within the normative range on follow-up, although one child had a relative weakness in the motor area and another child exhibited mild speech delay. Of the three clinically identified children with newborn screening results below the cut-off value, two were healthy and performed within the normal range on cognitive and motor tests at follow-up. Four clinically identified children with SCADD experienced persistent symptoms and/or developmental delay. However, in each of these cases, there were supplementary or alternative explanations for medical and neuropsychological deficits. Results indicated no genotype-phenotype correlations. These findings suggest that SCADD might be benign and the clinical symptoms ascribed to SCADD reflective of ascertainment bias or that early identification and treatment prevented complications that may have occurred due to interaction between genetic susceptibility and other genetic factors or environmental stressors.

Original languageEnglish (US)
Pages (from-to)39-45
Number of pages7
JournalMolecular Genetics and Metabolism
Volume95
Issue number1-2
DOIs
StatePublished - Sep 2008

Fingerprint

Butyryl-CoA Dehydrogenase
Screening
Newborn Infant
Nutrition
Language Development Disorders
Fat-Restricted Diet
Motor Cortex
Genetic Association Studies
Fats
Genetic Predisposition to Disease
Short chain Acyl CoA dehydrogenase deficiency
Reference Values

Keywords

  • Newborn screening
  • Psychological follow-up
  • Short-chain acyl-CoA dehydrogenase deficiency (SCADD)

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

Short-chain acyl-CoA dehydrogenase (SCAD) deficiency : An examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms. / Waisbren, S. E.; Levy, H. L.; Noble, M.; Matern, D.; Gregersen, N.; Pasley, K.; Marsden, D.

In: Molecular Genetics and Metabolism, Vol. 95, No. 1-2, 09.2008, p. 39-45.

Research output: Contribution to journalArticle

@article{fa56dac766454adca0f3877f4c775dce,
title = "Short-chain acyl-CoA dehydrogenase (SCAD) deficiency: An examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms",
abstract = "The medical and neurodevelopmental characteristics of 14 children with short-chain acyl-CoA dehydrogenase deficiency (SCADD) are described. Eight were detected as neonates by newborn screening. Three children diagnosed on the basis of clinical symptoms had normal newborn screening results while three were born in states that did not screen for SCADD. Treatment included frequent feedings and a low fat diet. All children identified by newborn screening demonstrated medical and neuropsychological development within the normative range on follow-up, although one child had a relative weakness in the motor area and another child exhibited mild speech delay. Of the three clinically identified children with newborn screening results below the cut-off value, two were healthy and performed within the normal range on cognitive and motor tests at follow-up. Four clinically identified children with SCADD experienced persistent symptoms and/or developmental delay. However, in each of these cases, there were supplementary or alternative explanations for medical and neuropsychological deficits. Results indicated no genotype-phenotype correlations. These findings suggest that SCADD might be benign and the clinical symptoms ascribed to SCADD reflective of ascertainment bias or that early identification and treatment prevented complications that may have occurred due to interaction between genetic susceptibility and other genetic factors or environmental stressors.",
keywords = "Newborn screening, Psychological follow-up, Short-chain acyl-CoA dehydrogenase deficiency (SCADD)",
author = "Waisbren, {S. E.} and Levy, {H. L.} and M. Noble and D. Matern and N. Gregersen and K. Pasley and D. Marsden",
year = "2008",
month = "9",
doi = "10.1016/j.ymgme.2008.06.002",
language = "English (US)",
volume = "95",
pages = "39--45",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - Short-chain acyl-CoA dehydrogenase (SCAD) deficiency

T2 - An examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms

AU - Waisbren, S. E.

AU - Levy, H. L.

AU - Noble, M.

AU - Matern, D.

AU - Gregersen, N.

AU - Pasley, K.

AU - Marsden, D.

PY - 2008/9

Y1 - 2008/9

N2 - The medical and neurodevelopmental characteristics of 14 children with short-chain acyl-CoA dehydrogenase deficiency (SCADD) are described. Eight were detected as neonates by newborn screening. Three children diagnosed on the basis of clinical symptoms had normal newborn screening results while three were born in states that did not screen for SCADD. Treatment included frequent feedings and a low fat diet. All children identified by newborn screening demonstrated medical and neuropsychological development within the normative range on follow-up, although one child had a relative weakness in the motor area and another child exhibited mild speech delay. Of the three clinically identified children with newborn screening results below the cut-off value, two were healthy and performed within the normal range on cognitive and motor tests at follow-up. Four clinically identified children with SCADD experienced persistent symptoms and/or developmental delay. However, in each of these cases, there were supplementary or alternative explanations for medical and neuropsychological deficits. Results indicated no genotype-phenotype correlations. These findings suggest that SCADD might be benign and the clinical symptoms ascribed to SCADD reflective of ascertainment bias or that early identification and treatment prevented complications that may have occurred due to interaction between genetic susceptibility and other genetic factors or environmental stressors.

AB - The medical and neurodevelopmental characteristics of 14 children with short-chain acyl-CoA dehydrogenase deficiency (SCADD) are described. Eight were detected as neonates by newborn screening. Three children diagnosed on the basis of clinical symptoms had normal newborn screening results while three were born in states that did not screen for SCADD. Treatment included frequent feedings and a low fat diet. All children identified by newborn screening demonstrated medical and neuropsychological development within the normative range on follow-up, although one child had a relative weakness in the motor area and another child exhibited mild speech delay. Of the three clinically identified children with newborn screening results below the cut-off value, two were healthy and performed within the normal range on cognitive and motor tests at follow-up. Four clinically identified children with SCADD experienced persistent symptoms and/or developmental delay. However, in each of these cases, there were supplementary or alternative explanations for medical and neuropsychological deficits. Results indicated no genotype-phenotype correlations. These findings suggest that SCADD might be benign and the clinical symptoms ascribed to SCADD reflective of ascertainment bias or that early identification and treatment prevented complications that may have occurred due to interaction between genetic susceptibility and other genetic factors or environmental stressors.

KW - Newborn screening

KW - Psychological follow-up

KW - Short-chain acyl-CoA dehydrogenase deficiency (SCADD)

UR - http://www.scopus.com/inward/record.url?scp=51649085510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649085510&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2008.06.002

DO - 10.1016/j.ymgme.2008.06.002

M3 - Article

VL - 95

SP - 39

EP - 45

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1-2

ER -